{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T02:40:17Z","timestamp":1792982417903,"version":"4.5.0"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02753-x","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T10:31:36Z","timestamp":1746700296000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["BCMA-targeted therapies in multiple myeloma: advances, challenges and future prospects"],"prefix":"10.1007","volume":"42","author":[{"given":"Ruhul","family":"Amin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biplab Kumar","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Darwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad","family":"Sharifi-Rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Calina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"issue":"9","key":"2753_CR1","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, Chojnacka M, Cirrincione A, Durante M, Tilmont R, Barakat E. Mechanisms of antigen escape from BCMA-or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29(9):2295\u2013306.","journal-title":"Nat Med"},{"key":"2753_CR2","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","volume":"9","author":"SF Cho","year":"2018","unstructured":"Cho SF, Anderson KC, Tai YT. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Front Immunol. 2018;9:1821.","journal-title":"Front Immunol"},{"key":"2753_CR3","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.3390\/cancers15082240","volume":"15","author":"L Xing","year":"2023","unstructured":"Xing L, Liu Y, Liu J. Targeting BCMA in multiple myeloma: advances in antibody-drug conjugate therapy. Cancers. 2023;15:2240.","journal-title":"Cancers"},{"issue":"18","key":"2753_CR4","doi-asserted-by":"publisher","first-page":"4088","DOI":"10.3390\/jcm10184088","volume":"10","author":"M Kleber","year":"2021","unstructured":"Kleber M, Ntanasis-Stathopoulos I, Terpos E. BCMA in multiple myeloma\u2014a promising key to therapy. J Clin Med. 2021;10(18):4088.","journal-title":"J Clin Med"},{"key":"2753_CR5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1055\/s-0043-1770149","volume":"58","author":"A Guedes","year":"2023","unstructured":"Guedes A, Becker RG, Teixeira LEM. Multiple myeloma (Part 1)\u2014update on epidemiology, diagnostic criteria, systemic treatment and prognosis. Rev Bras Ortop (Sao Paulo). 2023;58:361\u20137.","journal-title":"Rev Bras Ortop (Sao Paulo)"},{"key":"2753_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s43556-024-00188-w","volume":"5","author":"Q Lu","year":"2024","unstructured":"Lu Q, Yang D, Li H, Niu T, Tong A. Multiple myeloma: signaling pathways and targeted therapy. Mol Biomed. 2024;5:25.","journal-title":"Mol Biomed"},{"key":"2753_CR7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12967-022-03285-y","volume":"20","author":"ST Nobari","year":"2022","unstructured":"Nobari ST, Nojadeh JN, Talebi M. B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages. J Transl Med. 2022;20:82.","journal-title":"J Transl Med"},{"key":"2753_CR8","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/sj.leu.2402416","volume":"16","author":"RW CRAIG","year":"2002","unstructured":"CRAIG RW. MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia. 2002;16:444\u201354.","journal-title":"Leukemia"},{"key":"2753_CR9","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1182\/blood.2020006916","volume":"137","author":"ME Turnis","year":"2021","unstructured":"Turnis ME, Kaminska E, Smith KH, Kartchner BJ, Vogel P, Laxton JD, Ashmun RA, Ney PA, Opferman JT. Requirement for antiapoptotic MCL-1 during early erythropoiesis. Blood. 2021;137:1945\u201358.","journal-title":"Blood"},{"issue":"14","key":"2753_CR10","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.3390\/ijms21145002","volume":"21","author":"S Akhtar","year":"2020","unstructured":"Akhtar S, Ali TA, Faiyaz A, Khan OS, Raza SS, Kulinski M, Omri HE, Bhat AA, Uddin S. Cytokine-mediated dysregulation of signaling pathways in the pathogenesis of multiple myeloma. Int J Mol Sci. 2020;21(14):5002.","journal-title":"Int J Mol Sci"},{"key":"2753_CR11","doi-asserted-by":"crossref","unstructured":"Sun F, Cheng Y, Chen JR, Wanchai V, Mery DE, Xu H, Gai D, Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M. BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions. J Clin Invest. 2024; 134.","DOI":"10.1172\/JCI171396"},{"key":"2753_CR12","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2217\/imt.15.77","volume":"7","author":"YT Tai","year":"2015","unstructured":"Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015;7:1187\u201399.","journal-title":"Immunotherapy"},{"key":"2753_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","volume":"13","author":"CJ Ferreri","year":"2023","unstructured":"Ferreri CJ, Hildebrandt MA, Hashmi H, Shune LO, McGuirk JP, Sborov DW, Wagner CB, Kocoglu MH, Rapoport A, Atrash S. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023;13:117.","journal-title":"Blood Cancer J"},{"key":"2753_CR14","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34:985\u20131005.","journal-title":"Leukemia"},{"key":"2753_CR15","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.3390\/curroncol29070355","volume":"29","author":"ME Stalker","year":"2022","unstructured":"Stalker ME, Mark TM. Clinical management of Triple-Class refractory multiple myeloma: a review of current strategies and emerging therapies. Curr Oncol. 2022;29:4464\u201377.","journal-title":"Curr Oncol"},{"key":"2753_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","volume":"14","author":"Z Tian","year":"2021","unstructured":"Tian Z, Liu M, Zhang Y, Wang X. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J Hematol Oncol. 2021;14:75.","journal-title":"J Hematol Oncol"},{"key":"2753_CR17","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s40265-022-01793-1","volume":"82","author":"C KANG","year":"2022","unstructured":"KANG C. Teclistamab: first approval. Drugs. 2022;82:1613\u20139.","journal-title":"Drugs"},{"key":"2753_CR18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Mart\u00ednez-L\u00f3pez J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlar C, Stephenson T, van Rampelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, Usmani SZ. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495\u2013505.","journal-title":"N Engl J Med"},{"key":"2753_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000850960.38950.59","author":"R Fonseca","year":"2022","unstructured":"Fonseca R, Kuroda J, Ishida T, Popat R, Huang JS, Yver A, Vandendries E, Elmeliegy M, Ma WD, Sborov DW. PB2032: Magnetismm-9: an open-label, multicenter, non-randomized phase 1\/2 study of elranatamab in patients with relapsed\/refractory multiple myeloma. HemaSphere. 2022. https:\/\/doi.org\/10.1097\/01.HS9.0000850960.38950.59.","journal-title":"HemaSphere"},{"issue":"9","key":"2753_CR20","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, Rodr\u03afguez-Otero P, Martinez-Lopez J, Koehne G, Touzeau C, Jethava Y. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259\u201367.","journal-title":"Nat Med"},{"key":"2753_CR21","doi-asserted-by":"publisher","first-page":"e4258276","DOI":"10.1097\/01.HS9.0000975288.42582.76","volume":"7","author":"MVM Manteca","year":"2023","unstructured":"Manteca MVM, Grosicki S, Kim K, Negre E, Vandendries E. PB2131: Magnetismm-7: an open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly diagnosed multiple myeloma. HemaSphere. 2023;7:e4258276.","journal-title":"HemaSphere"},{"key":"2753_CR22","doi-asserted-by":"publisher","first-page":"1032775","DOI":"10.3389\/fonc.2022.1032775","volume":"12","author":"SF Cho","year":"2022","unstructured":"Cho SF, Yeh TJ, Anderson KC, Tai YT. Bispecific antibodies in multiple myeloma treatment: a journey in progress. Front Oncol. 2022;12:1032775.","journal-title":"Front Oncol"},{"key":"2753_CR23","doi-asserted-by":"publisher","first-page":"839097","DOI":"10.3389\/fimmu.2022.839097","volume":"13","author":"R Guo","year":"2022","unstructured":"Guo R, Lu W, Zhang Y, Cao X, Jin X, Zhao M. Targeting BCMA to treat multiple myeloma: updates from the 2021 ASH annual meeting. Front Immunol. 2022;13:839097.","journal-title":"Front Immunol"},{"key":"2753_CR24","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.18632\/oncotarget.27792","volume":"11","author":"CPM Verkleij","year":"2020","unstructured":"Verkleij CPM, Frerichs KA, Broekmans M, Absalah S, Maas-Bosman PWC, Kruyswijk S, Nijhof IS, Mutis T, Zweegman S, van de Donk N. T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma. Oncotarget. 2020;11:4076\u201381.","journal-title":"Oncotarget"},{"key":"2753_CR25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","volume":"22","author":"M Philip","year":"2022","unstructured":"Philip M, Schietinger A. CD8(+) T cell differentiation and dysfunction in cancer. Nat Rev Immunol. 2022;22:209\u201323.","journal-title":"Nat Rev Immunol"},{"issue":"18","key":"2753_CR26","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.3390\/cancers13184546","volume":"13","author":"J Krejcik","year":"2021","unstructured":"Krejcik J, Barnkob MB, Nyvold CG, Larsen TS, Barington T, Abildgaard N. Harnessing the immune system to fight multiple myeloma. Cancers. 2021;13(18):4546.","journal-title":"Cancers"},{"issue":"4","key":"2753_CR27","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1182\/bloodadvances.2022007625","volume":"7","author":"S Girgis","year":"2023","unstructured":"Girgis S, Wang Lin SX, Pillarisetti K, Verona R, Vieyra D, Casneuf T, Fink D, Miao X, Chen Y, Stephenson T, Banerjee A. Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed\/refractory multiple myeloma. Blood Adv. 2023;7(4):644\u20138.","journal-title":"Blood Adv"},{"key":"2753_CR28","doi-asserted-by":"publisher","first-page":"163","DOI":"10.6004\/jadpro.2023.14.2.7","volume":"14","author":"G Hua","year":"2023","unstructured":"Hua G, Scanlan R, Straining R, Carlson DS. Teclistamab-cqyv: the first bispecific T-Cell engager antibody for the treatment of patients with relapsed or refractory multiple myeloma. J Adv Pract Oncol. 2023;14:163\u201371.","journal-title":"J Adv Pract Oncol"},{"key":"2753_CR29","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s40265-023-01954-w","volume":"83","author":"S DHILLON","year":"2023","unstructured":"DHILLON S. Elranatamab: first approval. Drugs. 2023;83:1621\u20137.","journal-title":"Drugs"},{"key":"2753_CR30","doi-asserted-by":"publisher","first-page":"203636132312074","DOI":"10.1177\/20363613231207483","volume":"15","author":"T Rais","year":"2023","unstructured":"Rais T, Khan A, Riaz R. Elrexfio\u2122 (elranatamab-bcmm): the game-changer in treatment of multiple myeloma. Rare Tumors. 2023;15:20363613231207484.","journal-title":"Rare Tumors"},{"key":"2753_CR31","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1200\/JCO.19.02657","volume":"38","author":"MS Topp","year":"2020","unstructured":"Topp MS, Duell J, Zugmaier G, Attal M, Moreau P, Langer C, Kr\u00f6nke J, Facon T, Salnikov AV, Lesley R, Beutner K, Kalabus J, Rasmussen E, Riemann K, Minella AC, Munzert G, Einsele H. Anti-B-Cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma. J Clin Oncol. 2020;38:775\u201383.","journal-title":"J Clin Oncol"},{"key":"2753_CR32","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1182\/bloodadvances.2020002565","volume":"4","author":"RL Goldstein","year":"2020","unstructured":"Goldstein RL, Goyos A, Li CM, Deegen P, Bogner P, Sternjak A, Thomas O, Klinger M, Wahl J, Friedrich M, Rattel B, Lamas E, Min X, Sudom A, Farshbaf M, Coxon A, Balazs M, Arvedson T. AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys. Blood Adv. 2020;4:4180\u201394.","journal-title":"Blood Adv"},{"key":"2753_CR33","first-page":"1","volume":"3","author":"M Hartley-Brown","year":"2022","unstructured":"Hartley-Brown M, Richardson P. Antibody-drug conjugate therapies in multiple myeloma-what\u2019s next on the horizon? Explor Target Antitumor Ther. 2022;3:1\u201310.","journal-title":"Explor Target Antitumor Ther"},{"key":"2753_CR34","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1002\/ajh.26750","volume":"98","author":"S Leong","year":"2023","unstructured":"Leong S, Lam HPJ, Kirkham Z, Popat R. Antibody drug conjugates for the treatment of multiple myeloma. Am J Hematol. 2023;98:S22\u201334.","journal-title":"Am J Hematol"},{"issue":"10","key":"2753_CR35","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.3390\/vaccines9101111","volume":"9","author":"C Theocharopoulos","year":"2021","unstructured":"Theocharopoulos C, Lialios PP, Samarkos M, Gogas H, Ziogas DC. Antibody-drug conjugates: functional principles and applications in oncology and beyond. Vaccines. 2021;9(10):1111.","journal-title":"Vaccines"},{"key":"2753_CR36","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","volume":"10","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Hungria VTM, Radinoff A, Delimpasi S, Mikala G, Masszi T, Li J, Capra M, Maiolino A, Pappa V, Chraniuk D, Osipov I, Leleu X, Low M, Matsumoto M, Sule N, Li M, McKeown A, He W, Bright S, Currie B, Perera S, Boyle J, Roy-Ghanta S, Opalinska J, Weisel K. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023;10:e801\u201312.","journal-title":"Lancet Haematol"},{"key":"2753_CR37","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41375-020-0834-9","volume":"35","author":"HC Lee","year":"2021","unstructured":"Lee HC, Raje NS, Landgren O, Upreti VV, Wang J, Avilion AA, Hu X, Rasmussen E, Ngarmchamnanrith G, Fujii H, Spencer A. Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed\/refractory multiple myeloma. Leukemia. 2021;35:255\u20138.","journal-title":"Leukemia"},{"key":"2753_CR38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2020-136375","volume":"136","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Migkou M, Bhutani M, Spencer A, Ailawadhi S, Kalff A, Walcott F, Pore N, Gibson D, Wang F, Cheng L, Kagiampakis I, Williams M, Kinneer K, Jiang Y, Zonder J, Larsen J, Sirdesai S, Yee AJ, Dimopoulos MA. Phase 1, first-in-human study of MEDI2228, a BCMA-targeted ADC in patients with relapsed\/refractory multiple myeloma. Blood. 2020;136:26\u20137.","journal-title":"Blood"},{"key":"2753_CR39","doi-asserted-by":"publisher","first-page":"5376","DOI":"10.1158\/1078-0432.CCR-21-1621","volume":"27","author":"L Xing","year":"2021","unstructured":"Xing L, Wang S, Liu J, Yu T, Chen H, Wen K, Li Y, Lin L, Hsieh PA, Cho SF, An G, Qiu L, Kinneer K, Munshi N, Anderson KC, Tai YT. BCMA-specific ADC MEDI2228 and Daratumumab induce synergistic myeloma cytotoxicity via IFN-Driven immune responses and enhanced CD38 expression. Clin Cancer Res. 2021;27:5376\u201388.","journal-title":"Clin Cancer Res"},{"key":"2753_CR40","doi-asserted-by":"publisher","first-page":"590","DOI":"10.3390\/ph16040590","volume":"16","author":"U Ray","year":"2023","unstructured":"Ray U, Orlowski RZ. Antibody\u2013drug conjugates for multiple myeloma: just the beginning, or the beginning of the end? Pharmaceuticals. 2023;16:590.","journal-title":"Pharmaceuticals"},{"key":"2753_CR41","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1002\/cncr.34987","volume":"129","author":"AK Nooka","year":"2023","unstructured":"Nooka AK, Cohen AD, Lee HC, Badros A, Suvannasankha A, Callander N, Abdallah AO, Trudel S, Chari A, Libby EN, Chaudhry M, Hultcrantz M, Kort\u00fcm KM, Popat R, Sborov D, Hakim S, Lewis E, Gorsh B, Bhushan B, McKeown A, Gupta I, Opalinska J, Richardson PG, Lonial S. Single-agent belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: final analysis of the DREAMM-2 trial. Cancer. 2023;129:3746\u201360.","journal-title":"Cancer"},{"key":"2753_CR42","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facon T, Hulin C, Kort\u00fcm KM, Rodr\u00edguez-Otero P, Usmani SZ, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Piontek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Cohen AD. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207\u201321.","journal-title":"Lancet Oncol"},{"key":"2753_CR43","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1182\/blood-2023-178009","volume":"142","author":"VTM Hungria","year":"2023","unstructured":"Hungria VTM, Weisel K, Radinoff A, Delimpasi S, Mikala G, Masszi T, Li J, Capra M, Maiolino A, Pappa V, Chraniuk D, Osipov I, Leleu X, Low M, Matsumoto M, Li M, Sule N, Polinkovsky M, Davis R, Bright S, McKeown A, Opalinska J, Dimopoulos MA. Impact of long-term treatment with Belantamab Mafodotin on safety and efficacy outcomes in patients with relapsed\/refractory multiple myeloma in DREAMM-3. Blood. 2023;142:3357\u20133357.","journal-title":"Blood"},{"key":"2753_CR44","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41408-021-00592-3","volume":"11","author":"I Vaxman","year":"2021","unstructured":"Vaxman I, Abeykoon J, Dispenzieri A, Kumar SK, Buadi F, Lacy MQ, Dingli D, Hwa Y, Fonder A, Hobbs M, Reeder C, Sher T, Hayman S, Kourelis T, Warsame R, Muchtar E, Leung N, Go R, Gonsalves W, Siddiqui M, Kyle RA, Rajkumar SV, Kristen M, Kapoor P, Gertz MA. \u201cReal-life\u201d data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma\u2014the Mayo Clinic experience. Blood Cancer J. 2021;11:196.","journal-title":"Blood Cancer J"},{"key":"2753_CR45","doi-asserted-by":"publisher","first-page":"1398902","DOI":"10.3389\/fonc.2024.1398902","volume":"14","author":"K Miller","year":"2024","unstructured":"Miller K, Hashmi H, Rajeeve S. Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma. Front Oncol. 2024;14:1398902.","journal-title":"Front Oncol"},{"key":"2753_CR46","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","volume":"31","author":"M Sheykhhasan","year":"2024","unstructured":"Sheykhhasan M, Ahmadieh-Yazdi A, Vicidomini R, Poondla N, Tanzadehpanah H, Dirbaziyan A, Mahaki H, Manoochehri H, Kalhor N, Dama P. CAR T therapies in multiple myeloma: unleashing the future. Cancer Gene Ther. 2024;31:667\u201386.","journal-title":"Cancer Gene Ther"},{"key":"2753_CR47","doi-asserted-by":"crossref","unstructured":"Bui TA, Mei H, Sang R, Ortega DG, DENG W Advancements and challenges in developing <em>in&#xa0;vivo<\/em> CAR T cell therapies for cancer treatment. EBioMedicine. 2024; 106.","DOI":"10.1016\/j.ebiom.2024.105266"},{"key":"2753_CR48","doi-asserted-by":"publisher","first-page":"957157","DOI":"10.3389\/fimmu.2022.957157","volume":"13","author":"PS Rana","year":"2022","unstructured":"Rana PS, Murphy EV, Kort J, Driscoll JJ. Road testing new CAR design strategies in multiple myeloma. Front Immunol. 2022;13:957157.","journal-title":"Front Immunol"},{"issue":"11","key":"2753_CR49","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.3390\/vaccines11111721","volume":"11","author":"AK Mishra","year":"2023","unstructured":"Mishra AK, Gupta A, Dagar G, Das D, Chakraborty A, Haque S, Prasad CP, Singh A, Bhat AA, Macha MA, Benali M. CAR-T-Cell therapy in multiple myeloma: B-Cell maturation antigen (BCMA) and beyond. Vaccines. 2023;11(11):1721.","journal-title":"Vaccines"},{"key":"2753_CR50","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s40364-024-00634-5","volume":"12","author":"F Nasiri","year":"2024","unstructured":"Nasiri F, Asaadi Y, Mirzadeh F, Abdolahi S, Molaei S, Gavgani SP, Rahbarizadeh F. Updates on CAR T cell therapy in multiple myeloma. Biomark Res. 2024;12:102.","journal-title":"Biomark Res"},{"key":"2753_CR51","doi-asserted-by":"publisher","first-page":"720692","DOI":"10.3389\/fphar.2021.720692","volume":"12","author":"A Hern\u00e1ndez-L\u00f3pez","year":"2021","unstructured":"Hern\u00e1ndez-L\u00f3pez A, T\u00e9llez-Gonz\u00e1lez MA, Mondrag\u00f3n-Ter\u00e1n P, Meneses-Acosta A. Chimeric antigen Receptor-T cells: a pharmaceutical scope. Front Pharmacol. 2021;12:720692.","journal-title":"Front Pharmacol"},{"key":"2753_CR52","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1242\/dmm.018036","volume":"8","author":"M Sharpe","year":"2015","unstructured":"Sharpe M, Mount N. Genetically modified T cells in cancer therapy: opportunities and challenges. Dis Model Mech. 2015;8:337\u201350.","journal-title":"Dis Model Mech"},{"key":"2753_CR53","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.3389\/fimmu.2020.01128","volume":"11","author":"E Garc\u00eda-Guerrero","year":"2020","unstructured":"Garc\u00eda-Guerrero E, Sierro-Mart\u00ednez B, P\u00e9rez-Sim\u00f3n JA. Overcoming chimeric antigen receptor (CAR) modified T-cell therapy limitations in multiple myeloma. Front Immunol. 2020;11:1128.","journal-title":"Front Immunol"},{"key":"2753_CR54","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.21037\/atm.2018.11.14","volume":"6","author":"SF Cho","year":"2018","unstructured":"Cho SF, Anderson KC, Tai YT. BCMA CAR T-cell therapy arrives for multiple myeloma: a reality. Ann Transl Med. 2018;6:S93.","journal-title":"Ann Transl Med"},{"key":"2753_CR55","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/bjh.17544","volume":"195","author":"K Sanber","year":"2021","unstructured":"Sanber K, Savani B, Jain T. Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells. Br J Haematol. 2021;195:660\u20138.","journal-title":"Br J Haematol"},{"key":"2753_CR56","first-page":"802","volume":"14","author":"ML Davila","year":"2016","unstructured":"Davila ML, Brentjens RJ. CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2016;14:802\u20138.","journal-title":"Clin Adv Hematol Oncol"},{"key":"2753_CR57","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.3390\/curroncol30050334","volume":"30","author":"BE Monteith","year":"2023","unstructured":"Monteith BE, Sandhu I, Lee AS. Management of multiple myeloma: a review for general practitioners in oncology. Curr Oncol. 2023;30:4382\u2013401.","journal-title":"Curr Oncol"},{"key":"2753_CR58","doi-asserted-by":"publisher","first-page":"724411","DOI":"10.3389\/fimmu.2021.724411","volume":"12","author":"T Ma","year":"2021","unstructured":"Ma T, Shi J, Xiao Y, Bian T, Wang J, Hui L, Wang M, Liu H. Study on the relationship between the expression of B cell mature antigen and the classification, stage, and prognostic factors of multiple myeloma. Front Immunol. 2021;12:724411.","journal-title":"Front Immunol"},{"key":"2753_CR59","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s40265-022-01697-0","volume":"82","author":"B Paul","year":"2022","unstructured":"Paul B, Rodriguez C, Usmani SZ. BCMA-Targeted biologic therapies: the next standard of care in multiple myeloma therapy. Drugs. 2022;82:613\u201331.","journal-title":"Drugs"},{"key":"2753_CR60","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379:64\u201373.","journal-title":"N Engl J Med"},{"key":"2753_CR61","doi-asserted-by":"publisher","first-page":"e1049","DOI":"10.1002\/cti2.1049","volume":"8","author":"R Weinkove","year":"2019","unstructured":"Weinkove R, George P, Dasyam N, McLellan AD. Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clin Transl Immunology. 2019;8:e1049.","journal-title":"Clin Transl Immunology"},{"key":"2753_CR62","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","volume":"25","author":"J Feucht","year":"2019","unstructured":"Feucht J, Sun J, Eyquem J, Ho YJ, Zhao Z, Leibold J, Dobrin A, Cabriolu A, Hamieh M, Sadelain M. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat Med. 2019;25:82\u20138.","journal-title":"Nat Med"},{"issue":"8","key":"2753_CR63","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.3390\/v13081528","volume":"13","author":"RP Labb\u00e9","year":"2021","unstructured":"Labb\u00e9 RP, Vessillier S, Rafiq QA. Lentiviral vectors for T cell engineering: clinical applications, bioprocessing and future perspectives. Viruses. 2021;13(8):1528.","journal-title":"Viruses"},{"key":"2753_CR64","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3389\/fimmu.2020.00326","volume":"11","author":"LJB Brandt","year":"2020","unstructured":"Brandt LJB, Barnkob MB, Michaels YS, Heiselberg J, Barington T. Emerging approaches for regulation and control of CAR T cells: a mini review. Front Immunol. 2020;11:326.","journal-title":"Front Immunol"},{"key":"2753_CR65","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, Stewart AK, Hari P, Htut M, Lesokhin A. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324.","journal-title":"Lancet"},{"key":"2753_CR66","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.22.00690","volume":"41","author":"J-Q Mi","year":"2023","unstructured":"Mi J-Q, Zhao W, Jing H, Fu W, Hu J, Chen L, Zhang Y, Yao D, Chen D, Schecter JM. Phase II, open-label study of Ciltacabtagene Autoleucel, an Anti\u2013B-Cell Maturation antigen chimeric antigen Receptor\u2013T-Cell therapy, in Chinese patients with relapsed\/refractory multiple myeloma (CARTIFAN-1). J Clin Oncol. 2023;41:1275\u201384.","journal-title":"J Clin Oncol"},{"key":"2753_CR67","doi-asserted-by":"crossref","unstructured":"Lin Y, Martin TG, Usmani SZ, Berdeja JG, Jakubowiak AJ, Agha ME, Cohen AD, Deol A, Htut M, Lesokhin AM, Munshi NC. CARTITUDE-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma. Am Soc Clin Oncol. 2023.","DOI":"10.1016\/S2152-2650(23)00862-5"},{"issue":"11","key":"2753_CR68","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/JCO.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, Gonzalez R, Sborov DW, Wagner C, Dima D, Hashmi H. Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium. J Clin Oncol. 2023;41(11):2087\u201397.","journal-title":"J Clin Oncol"},{"key":"2753_CR69","doi-asserted-by":"publisher","first-page":"991092","DOI":"10.3389\/fimmu.2022.991092","volume":"13","author":"E Chekol Abebe","year":"2022","unstructured":"Chekol Abebe E, Yibeltal Shiferaw M, Tadele Admasu F, Asmamaw DT. Ciltacabtagene autoleucel: the second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. Front Immunol. 2022;13:991092.","journal-title":"Front Immunol"},{"key":"2753_CR70","doi-asserted-by":"publisher","first-page":"1070353","DOI":"10.3389\/fonc.2022.1070353","volume":"12","author":"R Banerjee","year":"2022","unstructured":"Banerjee R, Lee SS, Cowan AJ. Innovation in BCMA CAR-T therapy: building beyond the model T. Front Oncol. 2022;12:1070353.","journal-title":"Front Oncol"},{"key":"2753_CR71","doi-asserted-by":"publisher","first-page":"e897","DOI":"10.1016\/S2352-3026(22)00284-8","volume":"9","author":"T Martin","year":"2022","unstructured":"Martin T, Lin Y, Agha M, Cohen AD, Htut M, Stewart AK, Hari P, Berdeja JG, Usmani SZ, Yeh TM, Olyslager Y, Goldberg JD, Schecter JM, Madduri D, Jackson CC, Deraedt W, Gries KS, Fastenau JM, Trudeau JJ, Akram M, Pacaud L, Jakubowiak A, Jagannath S. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\u20132, open-label study. Lancet Haematol. 2022;9:e897\u2013905.","journal-title":"Lancet Haematol"},{"key":"2753_CR72","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, Moreau P, Yakoub-Agha I, Delforge M, Cavo M, Einsele H, Goldschmidt H, Weisel K, Rambaldi A, Reece D, Petrocca F, Massaro M, Connarn JN, Kaiser S, Patel P, Huang L, Campbell TB, Hege K, San-Miguel J. Idecabtagene Vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"2753_CR73","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jha2.312","volume":"3","author":"T Martin","year":"2022","unstructured":"Martin T, Krishnan A, Yong K, Weisel K, Mehra M, Nair S, Qi K, Londhe A, Diels J, Crivera C, Jackson CC, Olyslager Y, Vogel M, Schecter JM, Banerjee A, Valluri S, Usmani SZ, Berdeja JG, Jagannath S. Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician\u2019s choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma. EJHaem. 2022;3:97\u2013108.","journal-title":"EJHaem"},{"key":"2753_CR74","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","volume":"29","author":"Y Lin","year":"2023","unstructured":"Lin Y, Raje NS, Berdeja JG, Siegel DS, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Massaro M, Petrocca F, Yeri A, Finney O, Caia A, Yang Z, Martin N, Campbell TB, Rytlewski J, Fuller J, Hege K, Munshi NC, Kochenderfer JN. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med. 2023;29:2286\u201394.","journal-title":"Nat Med"},{"key":"2753_CR75","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","volume":"11","author":"WH Zhao","year":"2018","unstructured":"Zhao WH, Liu J, Wang BY, Chen YX, Cao XM, Yang Y, Zhang YL, Wang FX, Zhang PY, Lei B, Gu LF, Wang JL, Yang N, Zhang R, Zhang H, Shen Y, Bai J, Xu Y, Wang XG, Zhang RL, Wei LL, Li ZF, Li ZZ, Geng Y, He Q, Zhuang QC, Fan XH, He AL, Zhang WG. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018;11:141.","journal-title":"J Hematol Oncol"},{"key":"2753_CR76","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.htct.2020.10.466","volume":"42","author":"J Berdeja","year":"2020","unstructured":"Berdeja J, Madduri D, Usmani S, Singh I, Zudaire E, Yeh T, Allred A, Olyslager Y, Banerjee A, Goldberg J. Update of CARTITUDE-1: a phase 1b\/2 study of JNJ-68284528 (JNJ-4528), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T (CAR-T) cell therapy, in relapsed\/refractory multiple myeloma (MM). Hematol Transfus Cell Ther. 2020;42:279\u201380.","journal-title":"Hematol Transfus Cell Ther"},{"key":"2753_CR77","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1073\/pnas.1819745116","volume":"116","author":"J Xu","year":"2019","unstructured":"Xu J, Chen L-J, Yang S-S, Sun Y, Wu W, Liu Y-F, Xu J, Zhuang Y, Zhang W, Weng X-Q. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma. Proc Natl Acad Sci. 2019;116:9543\u201351.","journal-title":"Proc Natl Acad Sci"},{"key":"2753_CR78","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2018-CT130","author":"T Gregory","year":"2018","unstructured":"Gregory T, Berdeja J, Patel K, Ali SA, Cohen A, Costello C, Ostertag E, de Silva N, Shedlock D, Martin C. Clinical trial of P-BCMA-101 T stem cell memory (Tscm) CAR-T cells in relapsed\/refractory multiple myeloma. Cancer Res. 2018. https:\/\/doi.org\/10.1158\/1538-7445.AM2018-CT130.","journal-title":"Cancer Res"},{"key":"2753_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-018-0681-6","volume":"11","author":"W-H Zhao","year":"2018","unstructured":"Zhao W-H, Liu J, Wang B-Y, Chen Y-X, Cao X-M, Yang Y, Zhang Y-L, Wang F-X, Zhang P-Y, Lei B. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018;11:1\u20138.","journal-title":"J Hematol Oncol"},{"key":"2753_CR80","first-page":"141","volume":"2","author":"X Wang","year":"2019","unstructured":"Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019;2:141\u201360.","journal-title":"Cancer Drug Resist"},{"key":"2753_CR81","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.","journal-title":"Blood Cancer J"},{"key":"2753_CR82","doi-asserted-by":"publisher","DOI":"10.17925\/OHR.2022.18.1.59","author":"E Golden","year":"2022","unstructured":"Golden E, Ingram S, Schade H, Matous J, Gregory TK. Novel therapies in BCMA-exposed relapsed\/refractory multiple myeloma. the Anti-BCMA therapy-refractory patient. Oncol Haematol. 2022. https:\/\/doi.org\/10.17925\/OHR.2022.18.1.59.","journal-title":"Oncol Haematol"},{"key":"2753_CR83","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.3390\/cancers13184701","volume":"13","author":"I Strassl","year":"2021","unstructured":"Strassl I, Schreder M, Steiner N, Rudzki J, Agis H, K\u00fcnz T, M\u00fcser N, Willenbacher W, Petzer A, Neumeister P, Krauth MT. The agony of choice\u2014where to place the wave of BCMA-Targeted therapies in the multiple myeloma treatment puzzle in 2022 and beyond. Cancers. 2021;13:4701.","journal-title":"Cancers"},{"key":"2753_CR84","first-page":"418","volume":"29","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Jain MD, Smith EL. Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma. Transplant Cell Ther, Off Publ Am Soc Transplant Cell Ther. 2023;29:418\u201328.","journal-title":"Transplant Cell Ther, Off Publ Am Soc Transplant Cell Ther"},{"key":"2753_CR85","doi-asserted-by":"publisher","first-page":"096368972412939","DOI":"10.1177\/09636897241293964","volume":"33","author":"M Su","year":"2024","unstructured":"Su M, Zhang Z, Jiang P, Wang X, Tong X, Wu G. CAR-T-Cell therapy based on immune checkpoint modulation in the treatment of hematologic malignancies. Cell Transplant. 2024;33:09636897241293964.","journal-title":"Cell Transplant"},{"key":"2753_CR86","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1053\/j.seminoncol.2022.01.001","volume":"49","author":"T Mohammed","year":"2022","unstructured":"Mohammed T, Mailankody S. \u201cOff-the-shelf\u201d immunotherapies for multiple myeloma. Semin Oncol. 2022;49:60\u20138.","journal-title":"Semin Oncol"},{"issue":"3","key":"2753_CR87","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3390\/cells11030410","volume":"11","author":"F F\u00fcchsl","year":"2022","unstructured":"F\u00fcchsl F, Krackhardt AM. Adoptive cellular therapy for multiple myeloma using CAR-and TCR-transgenic T cells: response and resistance. Cells. 2022;11(3):410.","journal-title":"Cells"},{"key":"2753_CR88","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","volume":"127","author":"YT Tai","year":"2016","unstructured":"Tai YT, Acharya C, An G, Moschetta M, Zhong MY, Feng X, Cea M, Cagnetta A, Wen K, van Eenennaam H, van Elsas A, Qiu L, Richardson P, Munshi N, Anderson KC. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016;127:3225\u201336.","journal-title":"Blood"},{"key":"2753_CR89","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2147\/BLCTT.S327016","volume":"12","author":"MJ Rendo","year":"2022","unstructured":"Rendo MJ, Joseph JJ, Phan LM, Destefano CB. CAR T-Cell therapy for patients with multiple myeloma: current evidence and challenges. Blood Lymphat Cancer. 2022;12:119\u201336.","journal-title":"Blood Lymphat Cancer"},{"key":"2753_CR90","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2147\/CMAR.S372237","volume":"15","author":"D Pan","year":"2023","unstructured":"Pan D, Richter J. Teclistamab for multiple myeloma: clinical insights and practical considerations for a First-in-Class bispecific antibody. Cancer Manag Res. 2023;15:741\u201351.","journal-title":"Cancer Manag Res"},{"key":"2753_CR91","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1111\/bjh.19353","volume":"204","author":"A Hwang","year":"2024","unstructured":"Hwang A, Hayden P, Pawlyn C, McLornan D, Garderet L. The role of maintenance therapy following autologous stem cell transplantation in newly diagnosed multiple myeloma: considerations on behalf of the chronic Malignancies working party of the EBMT. Br J Haematol. 2024;204:1159\u201375.","journal-title":"Br J Haematol"},{"key":"2753_CR92","first-page":"705","volume":"16","author":"S Si","year":"2020","unstructured":"Si S, Teachey DT. Spotlight on Tocilizumab in the treatment of CAR-T-Cell-Induced cytokine release syndrome: clinical evidence to date. Ther Clin Risk Manag. 2020;16:705\u201314.","journal-title":"Ther Clin Risk Manag"},{"key":"2753_CR93","doi-asserted-by":"publisher","first-page":"1391698","DOI":"10.3389\/fonc.2024.1391698","volume":"14","author":"J Xia","year":"2024","unstructured":"Xia J, Wen Y, Xiao M, Ye D, Gao Y, Tang D, Zhang X, Chen J, Li Q, Yao Y. Sequential severe immune-related adverse events induced by PD-1 inhibitor: a case report and literature review. Front Oncol. 2024;14:1391698.","journal-title":"Front Oncol"},{"key":"2753_CR94","first-page":"163","volume":"36","author":"A Gajra","year":"2022","unstructured":"Gajra A, Zalenski A, Sannareddy A, Jeune-Smith Y, Kapinos K, Kansagra A. Barriers to chimeric antigen receptor T-Cell (CAR-T) therapies in clinical practice. Pharmaceut Med. 2022;36:163\u201371.","journal-title":"Pharmaceut Med"},{"key":"2753_CR95","doi-asserted-by":"publisher","first-page":"4812637","DOI":"10.1155\/2017\/4812637","volume":"2017","author":"A Hanbali","year":"2017","unstructured":"Hanbali A, Hassanein M, Rasheed W, Aljurf M, Alsharif F. The Evolution of Prognostic Factors in Multiple Myeloma. Adv Hematol. 2017;2017:4812637.","journal-title":"Adv Hematol"},{"key":"2753_CR96","doi-asserted-by":"publisher","first-page":"1240966","DOI":"10.3389\/fonc.2023.1240966","volume":"13","author":"R Banerjee","year":"2023","unstructured":"Banerjee R, Cicero KI, Lee SS, Cowan AJ. Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling. Front Oncol. 2023;13:1240966.","journal-title":"Front Oncol"},{"key":"2753_CR97","doi-asserted-by":"publisher","first-page":"117822421986823","DOI":"10.1177\/1178224219868235","volume":"13","author":"SA Bird","year":"2019","unstructured":"Bird SA, Boyd K. Multiple myeloma: an overview of management. Palliat Care Soc Pract. 2019;13:1178224219868235.","journal-title":"Palliat Care Soc Pract"},{"key":"2753_CR98","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s12920-021-01140-5","volume":"14","author":"M Ortiz-Est\u00e9vez","year":"2021","unstructured":"Ortiz-Est\u00e9vez M, Towfic F, Flynt E, Stong N, Jang IS, Wang K, Trotter MWB, Thakurta A. Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathways. BMC Med Genom. 2021;14:295.","journal-title":"BMC Med Genom"},{"key":"2753_CR99","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40164-024-00490-x","volume":"13","author":"Z Liu","year":"2024","unstructured":"Liu Z, Lei W, Wang H, Liu X, Fu R. Challenges and strategies associated with CAR-T cell therapy in blood malignancies. Exp Hematol Oncol. 2024;13:22.","journal-title":"Exp Hematol Oncol"},{"key":"2753_CR100","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s12935-022-02706-8","volume":"22","author":"ES Ali","year":"2022","unstructured":"Ali ES, Mitra K, Akter S, Ramproshad S, Mondal B, Khan IN, Islam MT, Sharifi-Rad J, Calina D, Cho WC. Recent advances and limitations of mTOR inhibitors in the treatment of cancer. Cancer Cell Int. 2022;22:284.","journal-title":"Cancer Cell Int"},{"key":"2753_CR101","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s12935-022-02777-7","volume":"22","author":"MJ Iqbal","year":"2022","unstructured":"Iqbal MJ, Javed Z, Herrera-Bravo J, Sadia H, Anum F, Raza S, Tahir A, Shahwani MN, Sharifi-Rad J, Calina D, Cho WC. Biosensing chips for cancer diagnosis and treatment: a new wave towards clinical innovation. Cancer Cell Int. 2022;22:354.","journal-title":"Cancer Cell Int"},{"key":"2753_CR102","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.mjafi.2021.06.021","volume":"77","author":"N Naithani","year":"2021","unstructured":"Naithani N, Sinha S, Misra P, Vasudevan B, Sahu R. Precision medicine: concept and tools. Med J Armed Forces India. 2021;77:249\u201357.","journal-title":"Med J Armed Forces India"},{"issue":"1","key":"2753_CR103","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3390\/ijms24010645","volume":"24","author":"D De Novellis","year":"2022","unstructured":"De Novellis D, Fontana R, Giudice V, Serio B, Selleri C. Innovative Anti-CD38 and Anti-BCMA targeted therapies in multiple myeloma: mechanisms of action and resistance. Int J Mol Sci. 2022;24(1):645.","journal-title":"Int J Mol Sci"},{"key":"2753_CR104","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s11899-021-00639-z","volume":"16","author":"CR Tan","year":"2021","unstructured":"Tan CR, Shah UA. Targeting BCMA in multiple myeloma. Curr Hematol Malig Rep. 2021;16:367\u201383.","journal-title":"Curr Hematol Malig Rep"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02753-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02753-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02753-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T04:05:33Z","timestamp":1748664333000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02753-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":104,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["2753"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02753-x","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not Applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"204"}}